Affymax pockets $60M in fourth round
VENTURE CAPITAL |
|||
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
Affymax
|
$60 million
|
JAFCO, Bear Stearns Health Innoventures |
Much of the money will go to a Phase II clinical program for Hematide in patients with chronic kidney disease and cancer. |
Ilypsa
|
$36 million
|
US Venture Partners, Johnson & Johnson Development Corporation, and Delphi Ventures |
Ilypsa will use the funds to complete preclinical and initiate clinical development of their two lead compounds ILY-101, a metal-free, polymeric phosphate binder, and ILY-105, a novel potassium-binding polymer. |
Labcyte
|
$21 million
|
Cross Atlantic Partners |
Labcyte is developing its low-volume liquid handling business, which is based on a proprietary technology for using focused acoustics to precisely transfer nanoliters of liquid. |
Peptimmune
|
$20.4 million
|
New Enterprise Associates |
Peptimmune's lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity. |
BrainCells
|
$17.7 million
|
Technology Partners, Oxford Bioscience Partners, and Bay City Capital |
The money will go to identify one or more late-stage clinical compounds currently under development for a CNS indication. |
APT Pharmaceuticals
|
$6 million
|
Charter Life Sciences |
The funds go to support a Phase II trial of an inhaled version of hydroxychloroquine for asthma. |